SCHEMBL863032

SCHEMBL863032

COC(=O)C(Cc1ccc(OC(C)=O)cc1)NC(C)=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
ITGB3 P05106 1/20 0.48
ITGA2B P08514 1/20 0.48
GAA P10253 1/20 0.48
RAB9A P51151 1/20 0.48
ATM Q13315 2/20 0.48
TDP2 O95551 1/20 0.48
PPARG P37231 1/20 0.47
TSHR P16473 1/20 0.47
TACR1 P25103 1/20 0.47
ALDH1A1 P00352 2/20 0.47
THRB P10828 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HDAC1 Q13547 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NOS3 P29474 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21510390 0.89 TACR1 (0.51) KMT2AITGB3ITGA2BGAARAB9A
SCHEMBL5706152 0.88 ACACB (0.58) KMT2AITGB3ITGA2BGAARAB9A
SCHEMBL6662892 0.88 ACACB (0.58) KMT2AITGB3ITGA2BGAARAB9A
SCHEMBL8472484 0.87 ITGB3 (0.48) KMT2ANPSR1ITGB3ITGA2BTDP2
SCHEMBL313883 0.87 ALDH1A1 (0.47) KMT2ANPSR1ITGB3ITGA2BGAA
SCHEMBL9335842 0.87 ACACB (0.43) ITGB3ITGA2BTSHRALDH1A1THRB
SCHEMBL9335847 0.87 ACACB (0.43) ITGB3ITGA2BTSHRALDH1A1THRB
SCHEMBL9337698 0.87 ITGB3 (0.62) KMT2AITGB3ITGA2BGAAPPARG
SCHEMBL11183676 0.87 ITGB3 (0.62) KMT2AITGB3ITGA2BGAAPPARG
SCHEMBL8477239 0.87 ITGB3 (0.62) KMT2AITGB3ITGA2BGAAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143366-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2012-03-27 US disclosed
US-20100081782-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME EKWURIBE NNOCHIRI N 2010-04-01 US disclosed
US-7625995-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2009-12-01 US disclosed
US-20080146778-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME BIOCON LIMITED (IN) 2008-06-19 US disclosed
US-7335751-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2008-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146778-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME ALK, AOX1, OGFR KMT2A 1543/4885NPSR1 217/4885ITGB3 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.